Anika Therapeutics | ANIK - Pre Tax Profit


Anika Therapeutics reported $764K in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
Agenus USD 39.21M 49.82M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -11.37M 150.72M Jun/2026
Integra LifeSciences USD -2.41M 6.72M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
J&J USD 8.66B 839M Jun/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Merit Medical Systems USD 53.55M 2.49M Mar/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR 837M 1.17B Jun/2026
Smith & Nephew USD 469M 70M Dec/2025
Stryker USD 850M 855M Mar/2026
Veracyte USD 26.52M 3.45M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026
Zimmer Biomet Holdings USD 487.5M 186.2M Jun/2026